Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Assets (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Assets for 5 consecutive years, with $327.7 million as the latest value for Q4 2025.

  • Quarterly Assets fell 6.69% to $327.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $327.7 million through Dec 2025, down 6.69% year-over-year, with the annual reading at $327.7 million for FY2025, 6.69% down from the prior year.
  • Assets hit $327.7 million in Q4 2025 for ARS Pharmaceuticals, down from $372.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $382.2 million in Q1 2021 to a low of $61.4 million in Q4 2021.
  • Historically, Assets has averaged $284.7 million across 5 years, with a median of $287.7 million in 2022.
  • Biggest YoY gain for Assets was 358.02% in 2022; the steepest drop was 23.12% in 2022.
  • Year by year, Assets stood at $61.4 million in 2021, then surged by 358.02% to $281.4 million in 2022, then fell by 17.14% to $233.2 million in 2023, then soared by 50.59% to $351.2 million in 2024, then fell by 6.69% to $327.7 million in 2025.
  • Business Quant data shows Assets for SPRY at $327.7 million in Q4 2025, $372.8 million in Q3 2025, and $313.5 million in Q2 2025.